Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Firefly discovers novel electrophysiological biomarker for PTSD

Firefly Neuroscience (NASDAQ: AIFF) has announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder (PTSD) using brain scans collected on its FDA-510(k)-cleared Evoke System...

June 2, 2026

Developments

Senzime launches new EMG sensor for anesthesia monitoring

Senzime (STO: SEZI; OTCQX: SNZZF) has announced the launch of its TetraSens electromyography (EMG) sensor for use with the TetraGraph Train-of-Four monitoring system for anesthesia monitoring. According to Senzime, the...

June 1, 2026

Executive Moves

Dr. John Lambert joins Defence BoD

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Dr. John Lambert to its board of directors (BoD), effective immediately. Internationally recognized, Dr. Lambert brings more than four decades of...

June 1, 2026

Developments

Sunshine announces Canadian approval of generic Rivaroxaban

Sunshine Biopharma (NASDAQ: SBFM) has announced the Canadian approval of Rivaroxaban—its generic equivalent of the brand Xarelto—in tablets of 2.5 mg, 10 mg, 15 mg, and 20 mg for the treatment and prevention of deep...

June 1, 2026

Developments

Cercare and Siemens announce global collaboration on CBCT-P guided stroke treatment

Closely held Cercare Medical and Siemens Healthineers (FSE: SHL) have announced a global collaboration to accelerate the adoption of Cone-Beam CT Perfusion (CBCT-P) in acute stroke care, leveraging its capability to...

May 28, 2026

Developments

BioXcel presents positive data for BXCL501 in bipolar or schizophrenia at ASCP

BioXcel Therapeutics (NASDAQ: BTAI) has announced new positive Phase 3 SERENITY At-Home data for BXCL501 in agitation associated with bipolar disorders or schizophrenia, to be presented this week at the 2026 American...

May 28, 2026

Executive Moves

Former FDA official Peter J. Pitts joins BrainStorm BoD

BrainStorm Cell Therapeutics (OTCQB: BCLI) has appointed former FDA associate commissioner, Peter J. Pitts, to its board of directors (BoD), effective immediately. Mr. Pitts is a globally recognized expert in healthcare...

May 28, 2026

Developments

Conexeu launches preclinical program for B.R.E.A.S.T. with WFIRM

Conexeu Sciences (NASDAQ: CNXU) has initiated a preclinical development program for B.R.E.A.S.T. (BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE), its recently unveiled 3D-printed bioregenerative breast matrix...

May 28, 2026

Developments

The iMRI revolution gets another boost from AiM’s collaboration with Siemens to advance robotic neurosurgery

Closely held AiM Medical Robotics has announced a collaboration agreement with Siemens Healthineers (FSE: SHL) for the implementation of an interface enabling AiM’s robotic platform to operate with MRI systems...

May 27, 2026

Markets

Clear Street starts LB Pharmaceuticals at buy; PT $45

Clear Street initiated coverage of LB Pharmaceuticals (NASDAQ: LBRX) with a “buy” rating and price target of $45.00. The stock closed at $28.33 on May 26th. LB Pharmaceuticals is a late-stage biopharmaceutical company...

May 26, 2026

Developments

Kura reports compelling data from trial of FTI in solid tumors

Kura Oncology (NASDAQ: KURA) has reported compelling first-in-human data from the FIT-001 clinical trial of its next-generation farnesyl transferase inhibitor (FTI) darlifarnib in combination with adagrasib in heavily...

May 26, 2026

Developments

Percheron secures pINN from WHO for investigational cancer therapy

Percheron Therapeutics (ASX: PER; OTC: PERCF) has secured a potential international nonproprietary name (pINN) from the World Health Organization (WHO) for its investigational cancer therapy HMBD-002. According to...

May 26, 2026

Subscribe